🎉 M&A multiples are live!
Check it out!

Abionyx Pharma Valuation Multiples

Discover revenue and EBITDA valuation multiples for Abionyx Pharma and similar public comparables like Armata Pharmaceuticals, Vivoryon Therapeutics, and Pharming.

Abionyx Pharma Overview

About Abionyx Pharma

Abionyx Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment. The biotech assets inherited from CERENIS Therapeutics constitute a portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as an HDL targeted drug delivery platform in oncology, more specifically in Immuno oncology and chemotherapy.


Founded

2005

HQ

France
Employees

5

Website

abionyx.com

Financials

LTM Revenue $5.0M

LTM EBITDA -$4.1M

EV

$44.2M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Abionyx Pharma Financials

Abionyx Pharma has a last 12-month revenue of $5.0M and a last 12-month EBITDA of -$4.1M.

In the most recent fiscal year, Abionyx Pharma achieved revenue of $5.1M and an EBITDA of -$3.7M.

Abionyx Pharma expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Abionyx Pharma valuation multiples based on analyst estimates

Abionyx Pharma P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $5.7M $5.1M XXX XXX XXX
Gross Profit $0.3M $0.7M XXX XXX XXX
Gross Margin 5% 14% XXX XXX XXX
EBITDA -$4.4M -$3.7M XXX XXX XXX
EBITDA Margin -76% -72% XXX XXX XXX
Net Profit -$6.4M -$4.6M XXX XXX XXX
Net Margin -111% -91% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Abionyx Pharma Stock Performance

As of March 14, 2025, Abionyx Pharma's stock price is EUR 1 (or $1).

Abionyx Pharma has current market cap of EUR 42.6M (or $46.5M), and EV of EUR 40.5M (or $44.2M).

See Abionyx Pharma trading valuation data

Abionyx Pharma Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$44.2M $46.5M XXX XXX XXX XXX n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Abionyx Pharma Valuation Multiples

As of March 14, 2025, Abionyx Pharma has market cap of $46.5M and EV of $44.2M.

Abionyx Pharma's trades at 8.8x LTM EV/Revenue multiple, and -10.7x LTM EBITDA.

Analysts estimate Abionyx Pharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Abionyx Pharma and 10K+ public comps

Abionyx Pharma Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $44.2M XXX XXX XXX
EV/Revenue 8.7x XXX XXX XXX
EV/EBITDA -12.1x XXX XXX XXX
P/E -12.1x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -10.6x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Abionyx Pharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Abionyx Pharma Valuation Multiples

Abionyx Pharma's NTM/LTM revenue growth is n/a

Abionyx Pharma's revenue per employee for the last fiscal year averaged $1.0M, while opex per employee averaged $0.8M for the same period.

Over next 12 months, Abionyx Pharma's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Abionyx Pharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Abionyx Pharma and other 10K+ public comps

Abionyx Pharma Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -12% XXX XXX XXX XXX
EBITDA Margin -72% XXX XXX XXX XXX
EBITDA Growth -17% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -72% XXX XXX XXX XXX
Revenue per Employee $1.0M XXX XXX XXX XXX
Opex per Employee $0.8M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 24% XXX XXX XXX XXX
R&D Expenses to Revenue 33% XXX XXX XXX XXX
Opex to Revenue 82% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Abionyx Pharma Public Comps

See public comps and valuation multiples for Biopharmaceuticals and Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
Armata Pharmaceuticals XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Abionyx Pharma M&A and Investment Activity

Abionyx Pharma acquired  XXX companies to date.

Last acquisition by Abionyx Pharma was  XXXXXXXX, XXXXX XXXXX XXXXXX . Abionyx Pharma acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Abionyx Pharma

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Abionyx Pharma

When was Abionyx Pharma founded? Abionyx Pharma was founded in 2005.
Where is Abionyx Pharma headquartered? Abionyx Pharma is headquartered in France.
How many employees does Abionyx Pharma have? As of today, Abionyx Pharma has 5 employees.
Is Abionyx Pharma publicy listed? Yes, Abionyx Pharma is a public company listed on PAR.
What is the stock symbol of Abionyx Pharma? Abionyx Pharma trades under ABNX ticker.
When did Abionyx Pharma go public? Abionyx Pharma went public in 2015.
Who are competitors of Abionyx Pharma? Similar companies to Abionyx Pharma include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics.
What is the current market cap of Abionyx Pharma? Abionyx Pharma's current market cap is $46.5M
What is the current revenue of Abionyx Pharma? Abionyx Pharma's last 12-month revenue is $5.0M.
What is the current EBITDA of Abionyx Pharma? Abionyx Pharma's last 12-month EBITDA is -$4.1M.
What is the current EV/Revenue multiple of Abionyx Pharma? Current revenue multiple of Abionyx Pharma is 8.8x.
What is the current EV/EBITDA multiple of Abionyx Pharma? Current EBITDA multiple of Abionyx Pharma is -10.7x.
What is the current revenue growth of Abionyx Pharma? Abionyx Pharma revenue growth between 2023 and 2024 was -12%.
Is Abionyx Pharma profitable? Yes, Abionyx Pharma is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.